Agenus director takes salary in 3,403 stock units
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Dr. Garo H. Armen received 3,403 shares of Common Stock as compensation for his salary for the pay period ending April 17, 2026. His salary is being paid in stock, in lieu of cash, under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan, and these shares are fully vested on the date of issuance.
The shares were valued at $4.79 per share, the closing price of Agenus Common Stock on April 17, 2026. After this grant, Dr. Armen directly holds 342,550 shares, and he also has indirect holdings through IRA accounts and trusts/partnerships, where he has varying degrees of investment authority and pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 3,403 shares
Grant/Award
3 txns
Insider
ARMEN GARO H
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 3,403 | $4.79 | $16K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 342,550 shares (Direct);
Common Stock — 60,248 shares (Indirect, See Footnote)
Footnotes (4)
- F1. At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending April 17, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.
- F2. $4.79 is the closing price of our Common Stock on April 17, 2026, the last trading day for the payroll date for the pay period ending April 17, 2026.
- F3. Shares are held in Dr. Armen's IRA accounts.
- F4. Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 5,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.
Key Figures
Stock salary grant: 3,403 shares
Grant valuation price: $4.79 per share
Direct holdings after grant: 342,550 shares
+2 more
5 metrics
Stock salary grant
3,403 shares
Net salary for pay period ending April 17, 2026
Grant valuation price
$4.79 per share
Closing price on April 17, 2026
Direct holdings after grant
342,550 shares
Common Stock directly held by Dr. Armen after transaction
IRA indirect holdings
28,950 shares
Common Stock held in Dr. Armen’s IRA accounts
GRAT and Pixie indirect holdings
31,298 shares
Common Stock held via GRAT and Pixie entities
Key Terms
2019 Equity Incentive, IRA accounts, GRAT, pecuniary interest
4 terms
2019 Equity Incentive financial
"Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive"
IRA accounts financial
"Shares are held in Dr. Armen's IRA accounts."
An IRA account is a tax-advantaged personal savings account designed to help people invest for retirement; think of it as a special piggy bank that gives you tax breaks to encourage long-term saving. Different IRA types change when you pay taxes and when you can take money out, so they matter to investors because the choice affects your after-tax returns, portfolio decisions, and the timing of withdrawals during retirement.
GRAT financial
"Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock."
pecuniary interest financial
"Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie"
FAQ
What did Dr. Garo H. Armen report in this Agenus (AGEN) Form 4?
Dr. Garo H. Armen reported receiving 3,403 shares of Agenus Common Stock as salary paid in stock instead of cash. The grant covers the pay period ending April 17, 2026 and is fully vested on issuance under the company’s 2019 Equity Incentive plan.
How is Dr. Armen’s salary structured according to this Agenus (AGEN) filing?
At his request and with Compensation Committee approval, Dr. Armen’s salary is paid in Agenus stock instead of cash. Shares are issued under the Amended and Restated 2019 Equity Incentive plan, are fully vested on the grant date, and reflect the net salary for each pay period.
What indirect Agenus (AGEN) holdings are associated with Dr. Armen?
Indirect holdings include shares in Dr. Armen’s IRA accounts and entities like the Garo Armen 2020 2 Year AG GRAT and Pixie Partners. He serves as trustee or general partner, and he disclaims beneficial ownership beyond his actual pecuniary interest in Pixie’s Agenus shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
